Thousands of people with type 2 diabetes across the UK will now have access to two powerful classes of medication much earlier in their treatment, following updated guidelines from the National Institute for Health and Care Excellence (NICE). This significant expansion could help prevent serious complications including heart attacks, strokes and kidney disease before they develop.
Previously, SGLT-2 inhibitors (such as dapagliflozin and empagliflozin) and GLP-1 receptor agonists (like semaglutide and liraglutide) were mainly reserved for type 2 diabetes patients who already had heart disease, heart failure, or kidney problems. Doctors prescribed these medications because strong clinical evidence showed they protected these specific organs whilst also lowering blood sugar levels. Under the new guidance, these drugs can now be offered more widely to patients whose diabetes isn't adequately controlled by metformin and lifestyle changes alone, even if they don't have existing complications.
This shift reflects mounting clinical evidence showing these medications do far more than simply control blood sugar. Both drug classes have demonstrated significant benefits in reducing cardiovascular events, slowing kidney disease progression, and preventing hospital admissions. By making them available to a broader group of patients earlier in their treatment journey, NICE aims to prevent these serious diabetes-related complications from developing in the first place.
The implications for the NHS are considerable. With approximately 4.3 million people living with diabetes in the UK—around 90% having type 2—this expanded access could dramatically improve long-term health outcomes. Whilst prescription costs will initially increase, the potential savings from preventing hospital admissions for heart attacks, strokes, and kidney failure could be substantial over time.
If you're currently managing type 2 diabetes, it's worth discussing these updated guidelines with your GP or diabetes specialist at your next appointment. Remember, any changes to your medication must always be made under medical supervision. For general health advice or concerns, contact your GP or call NHS 111.